Coronavirus disease (COVID-19) science conversation
In this video and audio series WHO experts explain the science related to COVID-19. This series is available every week on WHO's YouTube, Instagram, Facebook, Twitter, and LinkedIn channels and on all major podcasts platforms.
Download all epis...ode transcripts in Arabic, Chinese, English, French, Portuguese, Russian, Spanish, Hindi, Maithili, Nepali
more
Data received as of July 3, 2017 | WHO and UNICEF estimates of national immunization coverage - next revision available July 15, 2018
The new WHODAS 2.0 supersedes WHODAS II and shows the following advantages:
- A generic assessment instrument for health and disability
- Used across all diseases, including mental, neurological and addictive disorders
- Short, simple and easy to administer (5 to 20 minutes)
- Applicable in both... clinical and general population settings
- A tool to produce standardized disability levels and profiles
- Applicable across cultures, in all adult populations
- Directly linked at the level of the concepts to the International
- Classification of Functioning, Disability and Health (ICF)
more
Here you can find the latest reports
Q3: Can febrile seizures (simple or complex) be managed at first or second level care by non-specialist health care providers in low and middle income country settings? What is the role of diagnostic tests in the management of febrile seizures by non-specialists in low and middle income settings? Fo...r prophylaxis to prevent recurrence of simple or complex febrile seizures, which of the pharmacological interventions when compared with placebo/comparator produce benefit/harm in specified outcomes?
- continuous anticonvulsant therapy - intermittent anticonvulsant therapy - intermittent antipyretic treatment
more
Scoping Question: For adults and children living with HIV, which antiepileptic medications (such as phenobarbital, phenytoin, carbamazepine or valproic acid) produce benefits and/or harms when compared to a placebo or controls?
Bulletin of the World Health Organization; http://dx.doi.org/10.2471/BLT.16.176677
Ethiopia GATS was implemented by Ethiopia Public Health Institute (EPHI) in collaboration with the Ethiopian Food, Medicine, Health Care Administration and Control Authority (FMHACA), CSA, FMOH and the World Health Organization (WHO)country office. Technical assistance ...for the implementation of the survey was provided by the WHO, the U.S. Centers for Disease Control and Prevention (CDC), and RTI International. Program support was provided by the CDC Foundation.Financial support for Ethiopia GATS was provided by the CDC Foundation with a grant from the Bill & Melinda Gates Foundation.GATS enhances countries’ capacity to design, implement and evaluate tobacco control programs. It also assistscountries to fulfill their obligations under the WHO FCTC to generate comparable data within and across countries. In addition,it allows countries to implement the WHO MPOWER policy package. WHO MPOWERisa technical packagedevelopedtoassist countries in implementing selected demand reduction measures contained in the WHO Framework Convention on Tobacco Control(FCTC)(5).The six MPOWER evidence-based measures contained in the FCTC;
more
Standard Treatment Guideline
167,607 dengue cases, including 720 deaths, reported from 1 January to 27 July 2019: 97% higher than in 2018, in spite of a delayed rainy season.
Case Fatality Rate (CFR) of 0.43% as of 27 July 2019 is lower than in the same time period in 2018 (0.54%), but still significantly higher than the reg...ional average of 0.22% in the Western Pacific.
The Philippines Department of Health (DOH) declared a National Dengue Epidemic on 6 August 2019, urging all regional DOH offices to step up dengue surveillance, case management and outbreak re-sponse, clean-up drives, and vector control in health facilities and communities, conduct Sabayang 4-O’Clock Habit Para sa Deng-Get Out focusing on search and destroy of mosquito breeding sites, and to enable LGUs to use their quick response funds to help address the epidemic.
more
9 Febr. 2022
The COVID Covovax™ (SIIPL) and Nuvaxovid™ (Novavax) vaccine explainer includes key vaccine specific information on the vaccine specific requirements.